Selection of a Salvage Regimen for Relapsed or Refractory Classic Hodgkin Lymphoma in the Era of Novel Therapies.

The treatment landscape of classical Hodgkin lymphoma continues to evolve with earlier use of novel agents. Most recently, the addition of PD-1 inhibitors into frontline therapy has improved cure rates but introduced new challenges at relapse. How prior exposure to these agents impacts disease biology and response to salvage regimens remains unclear, thereby complicating second-line treatment decisions. This review discusses current considerations for selecting a salvage therapy in the era of frontline novel agents.